



## **Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business**

**Heidelberg, Germany and Cambridge, UK, 11 November 2019** – Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) announces the signing of an agreement with Abcam plc (London Stock Exchange: ABC; ISIN: GB00B6774699; AIM MTF), Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million. This purchase price is equivalent to twice Expedeon's current market capitalization or excess of 9-times 2018 annual group revenue. The agreement is subject to shareholder approval at an extraordinary meeting of Expedeon AG to be held in Heidelberg on December 19th, 2019.

The agreement covers the sale and transfer of all shares in Expedeon Holdings Limited (Cambridge, UK), organised in three divisions: the proteomics-focused Expedeon Ltd. and the two subdivisions within Expedeon's immunology portfolio, Innova Biosciences Ltd. (Cambridge, UK) and TGR BioSciences Pty Ltd. (Thebarton, Australia). Expedeon Inc (San Diego, USA) will be transferred from the Expedeon Holding Ltd. prior to the sale to become part of Expedeon AG (Heidelberg, Germany), the listed entity and parent company of Expedeon Holdings Ltd.. Expedeon Inc. will transfer the non-electrophoretic instrument assets to the purchaser. Following the transaction, Expedeon AG will change its corporate name and branding, which will be proposed to the extraordinary meeting.

Expedeon AG will retain approximately 38 % of its assets at the level of individual financial statements and 15 % at the level of consolidated financial statements. In the future, the Company will use parts of the proceeds of this transaction to apply its proven grow, buy and build strategy to its genomics business that it will continue to pursue through the remaining Spanish operation Expedeon Biotech S.L.U. (Madrid, Spain) and that is driven by its proprietary TruePrime™ technology. Future activities will include DNA manufacturing and establishing GMP certified facilities to supply DNA products for research, therapeutic and other uses requiring large amounts of high purity DNA, such the fast growing market of novel gene therapies.

\*\*\* end of ad hoc announcement \*\*\*

**For further information, please contact:**

**Expedeon AG**

Dr. Heikki Lanckriet

CEO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@expedeon.com](mailto:heikki.lanckriet@expedeon.com)

Investor website: [www.investors.expedeon.com](http://www.investors.expedeon.com)

## **MC Services AG (Investor Relations and International Media Relations)**

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: [expedeeon@mc-services.eu](mailto:expedeeon@mc-services.eu)

### **About Expedeon AG: [www.investors.expedeon.com](http://www.investors.expedeon.com)**

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###